Servier Pharmaceuticals

Servier Highlights Growing Neuro-Oncology Portfolio with New Data Across Pediatric and Adult Glioma at SNO 2026

Updated results from the four-year follow-up analysis of the Phase 2 FIREFLY-1 study provide additional information on the duration of response to…